Keytruda NSCLC Approval Will Test PD-L1 Expression

Labeling is specific for those with PD-L1 expression as measured with a new companion diagnostic and does not reference data for PD-L1 negative patients.

FDA’s approval of Merck & Co. Inc.’s Keytruda (pembrolizumab) in non-small cell lung cancer marks a turning point in development for the family of programmed death inhibitors in that it is the first approval targeted for patients with PD-L1 expression, measured with a new companion diagnostic.

On Oct. 2, the agency granted accelerated approval for Keytruda for patients with advanced (metastatic) NSCLC whose disease has progressed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

New EFPIA President Hopes ‘Sanity Will Prevail’ In EU Pharma Reform Dialogs

 

Stefan Oelrich, the newly-announced president of European pharma industry federation EFPIA says the EU pharma reform is “not an improvement on the status quo” in its current form.

UK Pilots Faster Setup Of Early Phase Oncology Trials

 
• By 

Oncology trial sponsors in the UK are being invited to participate in a pilot that aims to tackle duplication and variation in pharmacy reviews, which are an important part of setting up clinical trials in the National Health Service.

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.